Literature DB >> 11518779

Glycosylation of circulating IgA in patients with IgA nephropathy modulates proliferation and apoptosis of mesangial cells.

Alessandro Amore1, Paola Cirina1, Giovanni Conti1, Paola Brusa2, Licia Peruzzi1, Rosanna Coppo1.   

Abstract

Abnormalities in circulating IgA1 have been demonstrated in patients with IgA nephropathy (IgAN). This study addresses the question of the functional significance of this alteration in creating mesangial injury. Biologic effects of selected IgA glycoforms isolated from serum of IgAN patients and controls and in vitro deglycosylated normal IgA were tested on cultured human mesangial cells (MC). IgA glycoforms, ranging from 250 to 500 kD molecular weight, were isolated by lectin affinity chromatography followed by HPLC. IgA and IgG content was measured by enzyme-linked immunosorbent assay. HPLC fractions were incubated with MC to evaluate proliferation and apoptosis rates and nitric oxide synthesis. Moreover, MC were conditioned with in vitro desialylated and degalactosylated normal IgA. Patients with IgAN displayed increased levels of IgA glycoforms exposing sialic acid in alpha2,6 linkage with N-acetylgalactosamine (Neu5Acalpha2,6GalNAc) (P < 0.02) and GalNAc (P < 0.05), indicating truncation of O-linked glycans of IgA1. Moreover, IgA glycoforms with increased exposure of mannose were observed (P < 0.03), suggesting a defective N-linked glycosylation. No modification in IgG glycosylation was detected. When incubated with MC, the IgA glycoforms isolated from patients with increased exposure of GalNAc, Neu5Acalpha2,6GalNAc, or mannose, significantly depressed the proliferation and increased the apoptotic rate and nitric oxide synthesis activity of cultured MC, in comparison with fractions isolated from controls. Similarly, in vitro desialylated and degalactosylated IgAs significantly depressed the proliferation and enhanced the apoptosis rates of MC. In conclusion, a significant modulation of several human MC functions exerted by serum IgA with increased exposure of GalNAc, Neu5Acalpha2,6GalNAc, and mannose residues isolated from IgAN patients is reported for the first time.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11518779     DOI: 10.1681/ASN.V1291862

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  43 in total

1.  IgA and IgA-specific receptors in human disease: structural and functional insights into pathogenesis and therapeutic potential.

Authors:  Michelle M Gomes; Andrew B Herr
Journal:  Springer Semin Immunopathol       Date:  2006-10-17

2.  Development of immunoglobulin A nephropathy- like disease in beta-1,4-galactosyltransferase-I-deficient mice.

Authors:  Toshikazu Nishie; Osamu Miyaishi; Haruhito Azuma; Akihiko Kameyama; Chie Naruse; Noriyoshi Hashimoto; Hitoshi Yokoyama; Hisashi Narimatsu; Takashi Wada; Masahide Asano
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

3.  Can tonsillectomy modify the innate and adaptive immunity pathways involved in IgA nephropathy?

Authors:  Luca Vergano; Elisa Loiacono; Roberto Albera; Rosanna Coppo; Roberta Camilla; Licia Peruzzi; Alessandro Amore; Maria Elena Donadio; Federica Chiale; Alberto Boido; Filippo Mariano; Gianna Mazzucco; Sara Ravera; Giovanni Cancarini; Riccardo Magistroni; Giulietta Beltrame; Cristiana Rollino; Piero Stratta; Marco Quaglia; Roberto Bergia; Raffaella Cravero; Stefano Cusinato; Luisa Benozzi; Silvana Savoldi; Carola Licata
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

4.  C4d deposits in IgA nephropathy: where does complement activation come from?

Authors:  Rosanna Coppo
Journal:  Pediatr Nephrol       Date:  2017-02-14       Impact factor: 3.714

5.  In vitro-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cells.

Authors:  Takeshi Yanagihara; Rhubell Brown; Stacy Hall; Zina Moldoveanu; Alice Goepfert; Milan Tomana; Bruce A Julian; Jiri Mestecky; Jan Novak
Journal:  Results Immunol       Date:  2012-01-01

6.  Update on immunoglobulin A nephropathy, Part I: Pathophysiology.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2015-09-06

7.  Analysis of IgA1 N-glycosylation and its contribution to FcalphaRI binding.

Authors:  Michelle M Gomes; Stephanie B Wall; Kazuo Takahashi; Jan Novak; Matthew B Renfrow; Andrew B Herr
Journal:  Biochemistry       Date:  2008-10-01       Impact factor: 3.162

8.  Down-regulation of core 1 beta1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1.

Authors:  Koshi Yamada; Noriyoshi Kobayashi; Tomomi Ikeda; Yusuke Suzuki; Toshinao Tsuge; Satoshi Horikoshi; Steven N Emancipator; Yasuhiko Tomino
Journal:  Nephrol Dial Transplant       Date:  2010-06-15       Impact factor: 5.992

Review 9.  New perspectives in treatment of glomerulonephritis.

Authors:  Rosanna Coppo; Alessandro Amore
Journal:  Pediatr Nephrol       Date:  2003-12-13       Impact factor: 3.714

10.  Do the mutations of C1GALT1C1 gene play important roles in the genetic susceptibility to Chinese IgA nephropathy?

Authors:  Gui-Sen Li; Guang-Jun Nie; Hong Zhang; Ji-Cheng LV; Yan Shen; Hai-Yan Wang
Journal:  BMC Med Genet       Date:  2009-09-24       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.